About this episode
The multi-billion dollar weight-loss drug market has ballooned in the past few years. And the two pharmaceutical companies currently duking it out for market dominance, Novo Nordisk and Eli Lilly, have a century-long rivalry.
Bloomberg News health reporter Madison Muller breaks down how Eli Lilly developed Zepbound, a new drug that can help patients cut more than 20% of their body weight — and why some investors and analysts think it will turn Eli Lilly into the first ever trillion-dollar drug company.
(Corrects characterization of the current size of the weight-loss drug market)
See omnystudio.com/listener for privacy information.
Get every episode summarized
Each time Big Take publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
